Adaptive Biotechnologies Corp vs Northrop Grumman Corporation — how do they compare? Adaptive Biotechnologies Corp trades at $25.5 (market cap $4.04B), while Northrop Grumman Corporation trades at $574.85 (market cap $81.78B). The key difference: Northrop Grumman Corporation is far larger — about 20.2× Adaptive Biotechnologies Corp's market cap, and Northrop Grumman Corporation pays a 1.63% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | NOC | |
|---|---|---|
Market Cap | $4.04B | $81.78B |
Sector | Health | Industrials |
52-Week High | $25.45 | $768.02 |
52-Week Low | $12.30 | $496.02 |
Enterprise Value | $4.10B | $95.77B |
Dividend Yield | — | 1.63% |
Trailing returns across standard periods
Latest headlines on both assets
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →